Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children

Phase 2

Completed

Conditions: Medulloblastomas
Ependymomas
Supratentorial PNETs
Recurrent Brain Tumors

Interventions: Drug: temozolomide
Drug: carboplatin
Drug: temozolomide, thiotepa
Drug: etoposide
Drug: thiotepa, carboplatin, etoposide
Procedure: autologous stem cell transplantation
Drug: intraventricular etoposide
Drug: trofosfamide, etoposide

First Posted Date: 2008-09-09

Last Posted Date: 2018-07-20

Lead Sponsor: University Hospital, Bonn

Target Recruit Count: 174

Registration Number: NCT00749723

Locations: 🇩🇪
Universitätskinderklinik Freiburg, Freiburg, Germany
🇩🇪
Universitätskinderklinik Göttingen, Göttingen, Germany
🇩🇪
Universitätskinderklinik Heidelberg, Heidelberg, Germany

and more 51 locations

Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma

Phase 1

Completed

Conditions: Sarcoma

Interventions: Drug: cisplatin
Drug: dexrazoxane hydrochloride
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: ifosfamide
Drug: leucovorin calcium
Drug: methotrexate
Drug: zoledronic acid
Procedure: adjuvant therapy
Procedure: neoadjuvant therapy
Procedure: therapeutic conventional surgery
Biological: filgrastim
Drug: Mesna

First Posted Date: 2008-08-28

Last Posted Date: 2014-07-04

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 24

Registration Number: NCT00742924

Locations: 🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus, Atlanta, Georgia, United States
🇺🇸
Maine Children's Cancer Program at Barbara Bush Children's Hospital, Scarborough, Maine, United States

and more 85 locations

Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHL

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: Methylprednisolone
Drug: Etoposide
Drug: Cytarabine
Drug: Cisplatin
Drug: Rituximab
Drug: In-Zevalin
Drug: Y-Zevalin

First Posted Date: 2008-08-12

Last Posted Date: 2019-09-04

Lead Sponsor: University of Arizona

Target Recruit Count: 28

Registration Number: NCT00732498

Locations: 🇺🇸
The University of Arizona Cancer Center, Tucson, Arizona, United States

Sorafenib, Cisplatin, and Etoposide in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Phase 2

Terminated

Conditions: Lung Cancer

Interventions: Drug: cisplatin
Drug: etoposide
Drug: sorafenib tosylate

First Posted Date: 2008-08-01

Last Posted Date: 2014-11-19

Lead Sponsor: Afshin Dowlati, MD

Target Recruit Count: 18

Registration Number: NCT00726986

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸
MetroHealth Medical Center, Cleveland, Ohio, United States
🇺🇸
Columbia Presbyterian, New York, New York, United States

and more 8 locations

S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia

Phase 2

Withdrawn

Conditions: Lymphoma

Interventions: Biological: rituximab
Drug: bortezomib
Drug: carmustine
Drug: cisplatin
Drug: cyclophosphamide
Drug: cytarabine
Drug: dexamethasone
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: melphalan
Drug: thalidomide
Procedure: autologous-autologous tandem hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2008-07-29

Last Posted Date: 2015-03-06

Lead Sponsor: SWOG Cancer Research Network

Registration Number: NCT00723658

Locations: 🇺🇸
Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center, Hartford, Connecticut, United States
🇺🇸
St. Joseph Mercy Oakland, Pontiac, Michigan, United States
🇺🇸
Sparrow Regional Cancer Center, Lansing, Michigan, United States

and more 26 locations

Donor Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma

Phase 2

Conditions: Lymphoma

First Posted Date: 2008-07-22

Last Posted Date: 2013-08-02

Lead Sponsor: Cancer Research UK

Target Recruit Count: 25

Registration Number: NCT00720447

Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Phase 2

Completed

Conditions: Acute Lymphoblastic Leukemia
Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1

Interventions: Drug: Asparaginase
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Dasatinib
Drug: Daunorubicin Hydrochloride
Drug: Dexamethasone
Drug: Etoposide
Biological: Filgrastim
Drug: Hydrocortisone Sodium Succinate
Drug: Ifosfamide
Other: Laboratory Biomarker Analysis
Drug: Leucovorin Calcium
Drug: Mercaptopurine
Drug: Methotrexate
Drug: Methylprednisolone
Drug: Pegaspargase
Drug: Prednisone
Radiation: Radiation Therapy
Drug: Vincristine Sulfate

First Posted Date: 2008-07-22

Last Posted Date: 2020-04-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 63

Registration Number: NCT00720109

Locations: 🇺🇸
New York Medical College, Valhalla, New York, United States
🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Valley Children's Hospital, Madera, California, United States

and more 131 locations

Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases

Phase 2

Active, not recruiting

Conditions: Multiple Sclerosis Transplant
Chronic Inflammatory Demyelinating Polyneuropathy
Myasthenia Gravis
Rasmussen Subacute Encephalitis
Neurologic Autoimmune Disease
CIDP Transplant
Central Nervous System Vasculitis
Autoimmune Disease
Autologous Transplant Autoimmune
MS Stem Cell Transplant

Interventions: Biological: Anti-Thymocyte Globulin
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Carmustine
Drug: Cytarabine
Drug: Etoposide
Other: Laboratory Biomarker Analysis
Drug: Melphalan
Procedure: Peripheral Blood Stem Cell Transplantation
Drug: Prednisone
Procedure: Syngeneic Bone Marrow Transplantation

First Posted Date: 2008-07-16

Last Posted Date: 2024-07-18

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 53

Registration Number: NCT00716066

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
Swedish Medical Center-First Hill, Seattle, Washington, United States
🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States

Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia

Phase 3

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Cytarabine
Drug: Daunorubicin
Drug: Clofarabine
Drug: Etoposide
Device: CliniMACS

First Posted Date: 2008-06-24

Last Posted Date: 2021-08-10

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 324

Registration Number: NCT00703820

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Stanford University Medical Center, Palo Alto, California, United States
🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

and more 5 locations

Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies

Phase 1

Completed

Conditions: Acute Lymphoblastic Leukemia
Chronic Myelogenous Leukemia
Juvenile Myelomonocytic Leukemia
Myelodysplastic Syndrome
Non-Hodgkin's Lymphoma

Interventions: Other: NK Cell Infusion
Biological: Immunotherapy
Device: Miltenyi Biotec CliniMACS device
Drug: Interleukin-2 (IL-2)
Drug: Clofarabine
Drug: Cyclophosphamide
Drug: Etoposide

First Posted Date: 2008-06-16

Last Posted Date: 2013-07-16

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 48

Registration Number: NCT00697671

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy